 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ZEP-3 / Shulov Institute for Science
Trial completion date, Trial primary completion date: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Sep 13, 2023
P2, N=165, Recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
Trial completion date: Dec 2023 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- || ZEP-3 / Shulov Institute for Science
Trial completion date, Trial primary completion date: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Feb 10, 2023
P2, N=165, Recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
Trial completion date: Dec 2023 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || ZEP-3 / Shulov Institute for Science
Trial completion date, Trial primary completion date: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2022
P2, N=165, Recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || ZEP-3 / Shulov Institute for Science
Trial completion date, Trial primary completion date: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Mar 18, 2021
P2, N=165, Recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||| ZEP-3 / Shulov Institute for Science
New P2 trial: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Mar 12, 2020
P2, N=165, Recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
- |||| ZEP-3 / Shulov Institute for Science
Trial completion: Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores (clinicaltrials.gov) - May 30, 2019
P2, N=210, Completed, Sponsor: Shulov Innovate for Science Ltd. 2012
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Active, not recruiting --> Completed
- ||| ZEP-3 / Shulov Institute for Science
Enrollment closed, Trial completion date, Trial primary completion date: Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores (clinicaltrials.gov) - Apr 18, 2018
P2, N=210, Active, not recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2016 --> Jun 2018 | Trial primary completion date: Sep 2016 --> Jun 2018
- |||| ZEP-3 / Shulov Institute for Science
Enrollment open: Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores (clinicaltrials.gov) - Sep 30, 2015
P2, N=210, Recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
Recruiting --> Active, not recruiting | Trial completion date: Oct 2016 --> Jun 2018 | Trial primary completion date: Sep 2016 --> Jun 2018 Not yet recruiting --> Recruiting
- ||||| ZEP-3 / Shulov Institute for Science
New P2 trial: Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores (clinicaltrials.gov) - Jun 26, 2015
P2, N=210, Not yet recruiting, Sponsor: Shulov Innovate for Science Ltd. 2012
- | ZEP-3 / Shulov Institute for Science
Trial completion: Safety and Tolerability Study of ZEP-3 Cream (0.1% and 1.0%), Administered Topically In Healthy Volunteers (clinicaltrials.gov) - Feb 18, 2014
P1, N=22, Completed, Sponsor: Shulov Innovate for Science Ltd. 2012
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | ZEP-3 / Shulov Institute for Science
New P1 trial: Safety and Tolerability Study of ZEP-3 Cream (0.1% and 1.0%), Administered Topically In Healthy Volunteers (clinicaltrials.gov) - May 23, 2013
P1, N=22, Completed, Sponsor: Shulov Innovate for Science Ltd. 2012